Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) came out with its second-quarter results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. It looks like a credible result overall - although revenues of €252m were in line with what the analysts predicted, SCHOTT Pharma KGaA surprised by delivering a statutory profit of €0.26 per share, a notable 19% above expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the current consensus from SCHOTT Pharma KGaA's eleven analysts is for revenues of €1.02b in 2025. This would reflect a credible 4.6% increase on its revenue over the past 12 months. Per-share earnings are expected to rise 3.9% to €1.02. In the lead-up to this report, the analysts had been modelling revenues of €1.02b and earnings per share (EPS) of €1.02 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

View our latest analysis for SCHOTT Pharma KGaA

It will come as no surprise then, to learn that the consensus price target is largely unchanged at €28.61. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values SCHOTT Pharma KGaA at €37.00 per share, while the most bearish prices it at €20.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that SCHOTT Pharma KGaA's rate of growth is expected to accelerate meaningfully, with the forecast 9.5% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 6.2% over the past year. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 11% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that SCHOTT Pharma KGaA is expected to grow at about the same rate as the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at €28.61, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple SCHOTT Pharma KGaA analysts - going out to 2027, and you can see them free on our platform here.

You can also view our analysis of SCHOTT Pharma KGaA's balance sheet, and whether we think SCHOTT Pharma KGaA is carrying too much debt, for free on our platform here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.